Author:
Shalaby A K,Lewis K,Bush K,Meredith P R,Di Simplicio S,Lockwood A J
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Lock D . Avastin and Lucentis: a guide through the legal maze. BMJ 2015; 350: h1377.
2. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
3. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382: 1258–1267.
4. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2014; 9: CD011230.
5. Virgili G, Parravano M, Menchini F, Evans JR . Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 2014; 10: CD007419.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献